Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients

被引:15
|
作者
Kovacevic, Tijana [1 ,2 ]
Miljkovic, Branislava [3 ]
Kovacevic, Pedja [1 ,2 ]
Dragic, Sasa [1 ,2 ]
Momcicevic, Danica [1 ,2 ]
Avram, Sanja [1 ]
Jovanovic, Marija [3 ]
Vucicevic, Katarina [3 ]
机构
[1] Univ Clin Ctr Republ Srpska, Dvanaest Beba Bb, Banja Luka 78000, Bosnia & Herceg
[2] Univ Banja Luka, Fac Med, Save Mrkalja 14, Banja Luka 78000, Bosnia & Herceg
[3] Univ Belgrade, Fac Pharm, Dept Pharmacokinet & Clin Pharm, Vojvode Stepe 450, Belgrade 11221, Serbia
关键词
Creatinine clearance; NONMEM; Renal function; Antibiotics; TDM;
D O I
10.1016/j.jcrc.2019.10.012
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose: The present study aimed to establish a population pharmacokinetic model of vancomycin, including adult critically ill septic patients, with normal and impaired renal function. Materials and methods: A prospective analysis of 146 concentrations from 73 adult critically ill septic patients treated with 1-h intravenous infusion of vancomycin were included in the study. A nonlinear mixed effects modeling (NONMEM) approach was applied for data analysis and evaluation of the final model. The influence of creatinine clearance calculated by the Cockcroft-Gault equation (CrCl), and other potential covariates on vancomycin clearance (CL) were evaluated. Results: The final one-compartment pharmacokineticmodel includes the effect of CrCl on CL. Population pharmacokinetic values for a typical subject were estimated at 0.024 l/h for CL dependent on renal function (CLCrCl), 1.93 l/h for residual portion of CL (not dependent on renal function), and 0.511 l/kg for volume of distribution (V). According to the final model, for patients with CrCl = 120 ml/min, the median vancomycin total CL is 4.81 l/h, while CrCl-dependent fraction accounts for approximately 60% of CL. Conclusions: The developed population vancomycin modelmay be used in estimating individual CL for adult critically ill septic patients, and could be applied for individualizing dosage regimens taking into account the continuous effect of CrCl. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:116 / 121
页数:6
相关论文
共 50 条
  • [1] Population pharmacokinetic parameters of vancomycin in critically ill patients
    Llopis-Salvia, P.
    Jimenez-Torres, N. V.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (05) : 447 - 454
  • [2] Population Pharmacokinetic of Vancomycin Administered by Continuous Infusion in Critically Ill Patients
    Ben Romdhane, Haifa
    Woillard, Jean Baptiste
    Ben Fadhel, Najah
    Chadli, Zohra
    Chaabane, Amel
    Boughattas, Naceur
    Ben Fredj, Nadia
    Aouam, Karim
    PHARMACOLOGY, 2024,
  • [3] Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients
    Radke, Christian
    Horn, Dagmar
    Lanckohr, Christian
    Ellger, Bjoern
    Meyer, Michaela
    Eissing, Thomas
    Hempel, Georg
    CLINICAL PHARMACOKINETICS, 2017, 56 (07) : 759 - 779
  • [4] Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients
    Christian Radke
    Dagmar Horn
    Christian Lanckohr
    Björn Ellger
    Michaela Meyer
    Thomas Eissing
    Georg Hempel
    Clinical Pharmacokinetics, 2017, 56 : 759 - 779
  • [5] Therapeutic Drug Monitoring of Phenytoin in Critically Ill Patients
    von Winckelmann, Sandrina L.
    Spriet, Isabel
    Willems, Ludo
    PHARMACOTHERAPY, 2008, 28 (11): : 1391 - 1400
  • [6] β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
    Zeggil, Teagan
    Dalton, Bruce
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (12) : 2212 - 2213
  • [7] External Validation of Obese/Critically Ill Vancomycin Population Pharmacokinetic Models in Critically Ill Patients Who Are Obese
    Alsultan, Abdullah
    Dasuqi, Shereen A.
    Almohaizeie, Abdullah
    Aljutayli, Abdullah
    Aljamaan, Fadi
    Omran, Rasha A.
    Alolayan, Abdulaziz
    Hamad, Mohammed A.
    Alotaibi, Haifa
    Altamimi, Sarah
    Alghanem, Sarah S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (03): : 353 - 361
  • [8] POPULATION PHARMACOKINETIC EVALUATION OF VANCOMYCIN IN CRITICALLY ILL CHILDREN WITH SEPSIS
    Fitzgerald, Julie
    Zuppa, Athena
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 504 - 504
  • [9] Empirical models for dosage optimization of four β-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin
    Delattre, Isabelle K.
    Musuamba, Flora T.
    Verbeeck, Roger K.
    Dugernier, Thierry
    Spapen, Herbert
    Laterre, Pierre-Francois
    Wittebole, Xavier
    Cumps, Jean
    Taccone, Fabio S.
    Vincent, Jean-Louis
    Jacobs, Frederique
    Wallemacq, Pierre E.
    CLINICAL BIOCHEMISTRY, 2010, 43 (06) : 589 - 598
  • [10] FEASIBILITY OF TWO-LEVEL VANCOMYCIN AUC-BASED PHARMACOKINETIC MONITORING IN CRITICALLY ILL PATIENTS
    Briscoe, Abigale
    Nelson, Chad
    Sutton, Jesse
    Kerr, Thomas
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 330 - 330